- Home
- NBH vs BDTX Comparison
NBH vs BDTX Comparison
Compare NBH & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBH | BDTX |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 303.6M | 220.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NBH | BDTX |
|---|---|---|
| Price | $10.25 | $2.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.60 |
| AVG Volume (30 Days) | 85.9K | ★ 1.7M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.12 | ★ 0.38 |
| Revenue | N/A | ★ $70,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $87.04 | ★ $7.38 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.75 | $1.20 |
| 52 Week High | $11.01 | $4.94 |
Technical Indicators
Market Signals| Indicator | NBH | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.75 | 33.76 |
| Support Level | $10.22 | $2.61 |
| Resistance Level | $10.33 | $2.87 |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 66.67 | 33.82 |
Price Performance
Historical ComparisonAbout NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.